Pharmacogenetic considerations in the treatment of Parkinson's disease.

about

Parkinson's Disease: From Pathogenesis to Pharmacogenomics Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease.Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.

P2860

Q37729129-00410A23-3705-409C-90D5-D145730DA58B Q38748158-B84D77F8-07F5-467B-8D0F-55909655F12E Q47648607-2A33598B-D5E8-4C49-A213-5D2D85D7D327

P2860

Pharmacogenetic considerations in the treatment of Parkinson's disease.

Item

http://www.wikidata.org/entity/Q38364825

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Pharmacogenetic considerations in the treatment of Parkinson's disease.

@en

type

Item

label

Pharmacogenetic considerations in the treatment of Parkinson's disease.

@en

prefLabel

Pharmacogenetic considerations in the treatment of Parkinson's disease.

@en

P1476

Pharmacogenetic considerations in the treatment of Parkinson's disease.

@en

P2093

Marek Droździk

http://www.w3.org/2001/XMLSchema#string

Mateusz Kurzawski

http://www.w3.org/2001/XMLSchema#string

Monika Białecka

http://www.w3.org/2001/XMLSchema#string

P2860

Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment

Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD

Medical genetics: a marker for Stevens-Johnson syndrome

Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1

Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD

A knowledge base for the discovery of function, diagnostic potential and drug effects on cellular and extracellular miRNAs

Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing?

OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users

Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.

The genetics of Parkinson's disease: progress and therapeutic implications

P304

27-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/NMT.14.38

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272841596

http://www.w3.org/2001/XMLSchema#string

P698

25711452

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

Pharmacogenetic considerations in the treatment of Parkinson's disease.

about

P2860

P2860

Pharmacogenetic considerations in the treatment of Parkinson's disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921